PT2311434E - Formulações para inalador de pó seco compreendendo partículas modificadas na superfície com aditivos antiaderentes - Google Patents

Formulações para inalador de pó seco compreendendo partículas modificadas na superfície com aditivos antiaderentes Download PDF

Info

Publication number
PT2311434E
PT2311434E PT101790731T PT10179073T PT2311434E PT 2311434 E PT2311434 E PT 2311434E PT 101790731 T PT101790731 T PT 101790731T PT 10179073 T PT10179073 T PT 10179073T PT 2311434 E PT2311434 E PT 2311434E
Authority
PT
Portugal
Prior art keywords
particles
powder
magnesium stearate
lactose
active
Prior art date
Application number
PT101790731T
Other languages
English (en)
Portuguese (pt)
Inventor
David Morton
Original Assignee
Vectura Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33548732&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2311434(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vectura Ltd filed Critical Vectura Ltd
Publication of PT2311434E publication Critical patent/PT2311434E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Steroid Compounds (AREA)
PT101790731T 2004-11-23 2005-11-23 Formulações para inalador de pó seco compreendendo partículas modificadas na superfície com aditivos antiaderentes PT2311434E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0425758.0A GB0425758D0 (en) 2004-11-23 2004-11-23 Preparation of pharmaceutical compositions

Publications (1)

Publication Number Publication Date
PT2311434E true PT2311434E (pt) 2015-10-23

Family

ID=33548732

Family Applications (3)

Application Number Title Priority Date Filing Date
PT101790731T PT2311434E (pt) 2004-11-23 2005-11-23 Formulações para inalador de pó seco compreendendo partículas modificadas na superfície com aditivos antiaderentes
PT101515765T PT2174653E (pt) 2004-11-23 2005-11-23 Formulações para inalador de pó seco compreendendo partículas modificadas na superfície com aditivos antiaderentes
PT05808842T PT1814521E (pt) 2004-11-23 2005-11-23 Formulações para inalador de pó seco compreendendo partículas modificadas na superfície com aditivos antiaderentes

Family Applications After (2)

Application Number Title Priority Date Filing Date
PT101515765T PT2174653E (pt) 2004-11-23 2005-11-23 Formulações para inalador de pó seco compreendendo partículas modificadas na superfície com aditivos antiaderentes
PT05808842T PT1814521E (pt) 2004-11-23 2005-11-23 Formulações para inalador de pó seco compreendendo partículas modificadas na superfície com aditivos antiaderentes

Country Status (16)

Country Link
US (4) US20080127972A1 (enExample)
EP (4) EP2174653B1 (enExample)
JP (2) JP5339401B2 (enExample)
CN (2) CN104146960A (enExample)
AT (1) ATE456363T1 (enExample)
CA (1) CA2589514C (enExample)
DE (1) DE602005019192D1 (enExample)
DK (2) DK2311434T3 (enExample)
ES (3) ES2548884T3 (enExample)
GB (1) GB0425758D0 (enExample)
HU (1) HUE027465T2 (enExample)
IN (1) IN2014CN04336A (enExample)
PL (3) PL2174653T3 (enExample)
PT (3) PT2311434E (enExample)
SI (2) SI2174653T1 (enExample)
WO (1) WO2006056812A1 (enExample)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2283818B1 (en) 2000-11-30 2017-08-02 Vectura Limited Method of making particles for use in a pharmaceutical composition
WO2004073729A1 (ja) 2003-02-21 2004-09-02 Translational Research Ltd. 薬物の経鼻投与用組成物
AU2003220808B2 (en) 2003-03-27 2008-08-21 Bioactis Limited Powder medicine applicator for nasal cavity
US20120321717A1 (en) * 2003-04-14 2012-12-20 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
GB0327723D0 (en) 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
GB0321607D0 (en) 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
JP4922762B2 (ja) * 2004-08-10 2012-04-25 株式会社新日本科学 速効性でかつ高い吸収性を可能とする経鼻投与用組成物
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0621957D0 (en) * 2006-11-03 2006-12-13 Vectura Group Plc Inhaler devices and bespoke pharmaceutical compositions
US8337817B2 (en) 2006-12-26 2012-12-25 Shin Nippon Biomedical Laboratories, Ltd. Preparation for transnasal application
US20160331729A9 (en) * 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
EP3053440B1 (en) * 2007-04-11 2020-08-12 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
GB0712316D0 (en) * 2007-06-26 2007-08-01 Entripneur Ltd A novel powder and its method of manufacture
JP5570996B2 (ja) 2007-12-14 2014-08-13 エアロデザインズ インコーポレイテッド エアロゾル化可能な食料品の送達
BRPI0915783A2 (pt) 2008-07-18 2018-05-22 Prosonix Ltd processo para aumentar a cristalinidade de pelo menos um material sólido, partícula, composição farmacêutica ou agroquímica , e, inalador
EP2410981B2 (en) 2009-03-26 2020-02-26 Pulmatrix Operating Company, Inc. Dry powder formulations and methods for treating pulmonary diseases
GB0905840D0 (en) * 2009-04-06 2009-05-20 Sagentia Ltd Apparatus and methods
MX2011011123A (es) * 2009-04-24 2011-11-04 Schering Corp Formulaciones de aglomerado utiles en inhaladores de polvo seco.
EP2429495A4 (en) * 2009-05-15 2014-01-22 Shin Nippon Biomedical Lab Ltd INTRANASAL PHARMACEUTICAL COMPOSITION WITH IMPROVED PHARMACOKINETICS
GB2472327B (en) 2009-07-31 2013-03-13 Shin Nippon Biomedical Lab Ltd Intranasal granisetron and nasal applicator
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
GB0918431D0 (en) 2009-10-21 2009-12-09 Prosonix Ltd Process for improving crystallinity
EP2552424B1 (en) * 2010-04-01 2018-05-09 Chiesi Farmaceutici S.p.A. Process for preparing carrier particles for dry powders for inhalation
HRP20180488T1 (hr) * 2010-04-21 2018-07-13 Chiesi Farmaceutici S.P.A. Postupak priprave čestica sa smanjenim elektrostatičkim nabojem
CN102309456B (zh) * 2010-07-02 2013-05-01 北京化工大学 一种厄贝沙坦纳微复合粉体与片剂及其制备方法
US9061352B2 (en) 2010-08-30 2015-06-23 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
WO2012030647A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
CN107096014B (zh) 2010-09-29 2022-07-15 普马特里克斯营业公司 吸入用单价金属阳离子干粉剂
CA2812417C (en) 2010-09-29 2019-10-22 Pulmatrix, Inc. Cationic dry powders
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
ITMI20120092A1 (it) * 2012-01-26 2013-07-27 Micro Macinazione S A Compositi di inclusione farmaco-carrier preparati con processo di attivazione meccano-chimica mediante mulini a getto di fluido ad alta energia
CN104487075A (zh) * 2012-02-29 2015-04-01 普马特里克斯公司 可吸入干粉剂
SG11201404522VA (en) 2012-03-13 2014-10-30 Respivert Ltd Crystalline pi3 kinase inhibitors
RU2666963C2 (ru) 2012-04-13 2018-09-13 Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Агрегированные частицы
CN103570610B (zh) * 2012-07-18 2017-08-11 重庆华邦制药有限公司 一种罗氟司特微粒的制备方法
CN103588846B (zh) * 2012-08-15 2016-08-03 重庆华邦制药有限公司 一种丙酸氟替卡松微粒的制备方法及其用途
WO2014074797A1 (en) * 2012-11-09 2014-05-15 Civitas Therapeutics, Inc. Ultra low density pulmonary powders
JP6116206B2 (ja) * 2012-11-26 2017-04-19 クリニプロ株式会社 吸入用パウダーの製造方法
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
GB201305825D0 (en) 2013-03-28 2013-05-15 Vectura Ltd New use
WO2014165303A1 (en) 2013-04-01 2014-10-09 Pulmatrix, Inc. Tiotropium dry powders
ITMI20130572A1 (it) * 2013-04-10 2014-10-11 Eratech Srl Composizione comprendente almeno due polveri secche ottenute per spray dry per aumentare la stabilita' della formulazione
US10149823B2 (en) * 2013-04-30 2018-12-11 Otitopic Inc. Dry powder formulations and methods of use
CN105338960B (zh) 2013-07-11 2019-06-04 奇斯药制品公司 用于吸入施用的包含抗胆碱能药、皮质类固醇和β-肾上腺素能药的干粉制剂
CA2926719C (en) 2013-10-08 2020-11-24 Lam Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
WO2015089105A1 (en) 2013-12-09 2015-06-18 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
US10307371B2 (en) 2014-02-11 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
CN112656780A (zh) * 2014-02-20 2021-04-16 奥迪托皮克股份有限公司 用于吸入的干粉制剂
RS64482B1 (sr) 2014-04-04 2023-09-29 Ai Therapeutics Inc Inhalaciona formulacija rapamicina za lečenje stanja povezanih sa starenjem
US20180021256A1 (en) 2014-07-09 2018-01-25 Arven Ilac Sanayi Ve Ticaret A.S. Process for the preparation of formulations for inhalation
CN116687887A (zh) 2014-07-31 2023-09-05 维克图拉公司 用于吸入的干粉制剂
RS60299B1 (sr) 2014-09-09 2020-07-31 Vectura Ltd Formulacija koja obuhvata glikopirolat, postupak i uređaj
AU2015330905B2 (en) 2014-10-07 2021-02-25 AI Therapeutics, Inc. An inhalable rapamycin formulation for the treatment of pulmonary hypertension
US20160119692A1 (en) * 2014-10-24 2016-04-28 Sunshine Partners LLC Interactive system and method for viewer selection of objects in context while viewing television
CN107106641B (zh) 2014-10-31 2021-12-21 葛兰素史密斯克莱知识产权发展有限公司 粉末制剂
PE20180690A1 (es) 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
US10149844B2 (en) 2015-09-16 2018-12-11 Philip Morris Products S.A. Inhalable nicotine formulations, and methods of making and using thereof
US9585835B1 (en) * 2015-09-16 2017-03-07 Sansa Corporation (Barbados) Inc. Inhalable nicotine formulations and methods of making and using the same
WO2017218341A1 (en) 2016-06-17 2017-12-21 Axon Enterprise, Inc. Systems and methods for aligning event data
CN109310622A (zh) * 2016-06-30 2019-02-05 菲利普莫里斯生产公司 尼古丁颗粒和组合物
ES3005760T3 (en) * 2016-06-30 2025-03-17 Philip Morris Products Sa Nicotine particles
RU2766086C2 (ru) * 2016-10-14 2022-02-07 Пулматрикс Оперэйтинг Компани, Инк. Противогрибковые сухие порошки
RU2770039C2 (ru) * 2017-03-07 2022-04-14 Филип Моррис Продактс С.А. Вдыхаемые составы на основе никотина и способы их получения и применения
EP3630245A1 (en) 2017-06-02 2020-04-08 CSP Technologies, Inc. Inhaler and methods of using and making same
CN109200034A (zh) * 2017-06-30 2019-01-15 正大天晴药业集团股份有限公司 一种可吸入干粉形式的组合物及其制备方法
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
AU2017432640B2 (en) 2017-09-22 2023-11-30 Aspeya US Inc. Dry powder compositions with magnesium stearate
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
US11278492B2 (en) 2018-01-05 2022-03-22 Impel Neuropharma, Inc. Intranasal delivery of olanzapine by precision olfactory device
CN112451509B (zh) * 2020-12-19 2023-03-07 沈阳药科大学 一种川丁特罗吸入粉雾剂及其制备方法
WO2023069028A1 (en) * 2021-10-20 2023-04-27 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi A process for the preparation of dry powder compositions for inhalation
US12005185B2 (en) * 2021-12-17 2024-06-11 Belhaven BioPharma Inc. Medical counter measures including dry powder formulations and associated methods
WO2023128913A1 (en) * 2021-12-31 2023-07-06 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi A process for the preparation of dry powder compositions for inhalation
CN120152700A (zh) 2022-07-04 2025-06-13 好利安科技有限公司 涂覆的晶体干粉的用于吸入的干粉吸入器药物组合物
CN115060832B (zh) * 2022-08-18 2022-11-29 上海奥科达生物医药科技有限公司 奥卡西平口服混悬液中奥卡西平及防腐剂含量检测方法
CN115770221A (zh) * 2022-12-29 2023-03-10 浙江上药九旭药业有限公司 银杏酮酯粉体、银杏酮酯滴丸剂及其制备方法
GB2641869A (en) 2023-08-30 2025-12-17 Envirohale Malta Holdings Ltd Nasal and pulmonary drug delivery
CN120678762A (zh) * 2024-03-20 2025-09-23 浙江萃泽医药科技有限公司 一种可吸入的药物粉末制剂及其制备方法
CN119055610A (zh) * 2024-08-27 2024-12-03 江苏谦仁生物科技有限公司 一种阿昔莫司胶囊及其制备方法
CN119371006B (zh) * 2024-11-06 2025-07-04 北京城市排水集团有限责任公司 一种长效缓释型污泥脱氮菌群调节药剂及制备方法和应用

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4687773A (en) 1983-03-28 1987-08-18 Mclean Hospital (+)-N-N-propylnorapomorphine and selective limbic activity
WO1990013327A1 (en) 1989-04-28 1990-11-15 Riker Laboratories, Inc. Dry powder inhalation device
JPH05963A (ja) 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
US5292520A (en) 1990-09-13 1994-03-08 Akzo N.V. Stabilized solid pharmaceutical composition containing acid addition salts of a basic drug and an alkaline stabilizer
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
SA95160463B1 (ar) 1994-12-22 2005-10-04 استرا أكتيبولاج مساحيق للاستنشاق
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9515182D0 (en) 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
FR2747311B1 (fr) 1996-04-10 1998-08-14 Pf Medicament Inhalateur a poudre et a air comprime
ES2236832T3 (es) 1997-01-16 2005-07-16 Massachusetts Institute Of Technology Preparacion de particulas para inhalacion.
US6051257A (en) 1997-02-24 2000-04-18 Superior Micropowders, Llc Powder batch of pharmaceutically-active particles and methods for making same
EP0931595A1 (en) 1998-01-26 1999-07-28 Imra Europe S.A. A device for spraying a liquid
US6257233B1 (en) 1998-06-04 2001-07-10 Inhale Therapeutic Systems Dry powder dispersing apparatus and methods for their use
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
HU226164B1 (en) 1998-11-13 2008-05-28 Jagotec Ag Use of magnesium stearate in dry powder compositions suitable for inhalation and compositions suitable for inhalation
GB9827145D0 (en) 1998-12-09 1999-02-03 Co Ordinated Drug Dev Improvements in or relating to powders
PT1158958E (pt) 1999-03-05 2007-08-13 Chiesi Farma Spa ''composições farmacêuticas em pó, melhoradas, para inalação''
DK1180020T4 (da) 1999-05-27 2009-10-05 Acusphere Inc Poröse lægemiddelmatrixer og fremgangsmåder til fremstilling deraf
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
GB2353222B (en) 1999-06-23 2001-09-19 Cambridge Consultants Inhalers
US6586008B1 (en) 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
US20010036481A1 (en) 1999-08-25 2001-11-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
JP2001151673A (ja) 1999-09-06 2001-06-05 Nikken Chem Co Ltd 吸入用粉末製剤の製造方法
JP2001072586A (ja) 1999-09-06 2001-03-21 Nikken Chem Co Ltd 吸入用粉末製剤及びその製造方法
HU225917B1 (en) 1999-09-16 2007-12-28 Tanabe Seiyaku Co Pyrimidine and pyrazine derivatives, pharmaceutical compositions containing them and their use
FI20002217A7 (fi) 1999-12-30 2001-07-01 Orion Yhtymae Oyj Inhalaatiopartikkelit
GB0008411D0 (en) * 2000-04-05 2000-05-24 Vectura Ltd Pharmaceutical preparations and their manufacture
SK15772002A3 (sk) 2000-04-07 2003-09-11 Tap Pharmaceutical Products Inc. Deriváty apomorfínu, ich použitie a farmaceutická kompozícia s ich obsahom
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
AU782841B2 (en) 2000-04-17 2005-09-01 Vectura Limited Improvements in or relating to formulations for use in inhaler devices
GB0009469D0 (en) * 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
GB0009468D0 (en) * 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formulations for use in inhaler devices
GB0010709D0 (en) * 2000-05-03 2000-06-28 Vectura Ltd Powders for use a in dry powder inhaler
WO2002000197A1 (en) 2000-06-27 2002-01-03 Vectura Limited Method of making particles for use in a pharmaceutical composition
GB2364919A (en) 2000-07-21 2002-02-13 Cambridge Consultants Inhalers
AU2001277230A1 (en) 2000-08-01 2002-02-13 Inhale Therapeutic Systems, Inc. Apparatus and process to produce particles having a narrow size distribution andparticles made thereby
US6613308B2 (en) 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
WO2002039879A2 (en) 2000-11-15 2002-05-23 Tap Pharmaceutical Products, Inc. Treatment of anti-depression drug-induced sexual dysfunction with apomorphine
US20020086876A1 (en) 2000-11-15 2002-07-04 Ruff Dustin D. Treatment of anti-depression drug-induced sexual dysfunction with apomorphine
AU2002222118A1 (en) * 2000-11-30 2002-06-11 Vectura Limited Pharmaceutical compositions for inhalation
AU2002215114A1 (en) * 2000-11-30 2002-06-11 Vectura Limited Pharmaceutical compositions for inhalation
EP2168571B1 (en) * 2000-11-30 2018-08-22 Vectura Limited Particles for use in a Pharmaceutical Composition
EP2283818B1 (en) * 2000-11-30 2017-08-02 Vectura Limited Method of making particles for use in a pharmaceutical composition
US6660249B2 (en) 2000-12-27 2003-12-09 Salus Pharma, Inc. Inhalable dry powder aztreonam for treatment and prevention of pulmonary bacterial infections
GB0109384D0 (en) * 2001-04-12 2001-05-30 Vectura Ltd Pharmaceutical products, preparation and uses thereof
WO2002089879A1 (en) 2001-05-10 2002-11-14 Vectura Delivery Devices Limited Inhalers
GB2375308A (en) 2001-05-10 2002-11-13 Cambridge Consultants Inhalers
US6737042B2 (en) 2001-05-24 2004-05-18 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US20040028613A1 (en) 2001-06-25 2004-02-12 Nastech Pharmaceutical Company Inc Dopamine agonist formulations for enhanced central nervous system delivery
WO2003020241A2 (en) * 2001-09-05 2003-03-13 Vectura Limited Functional powders for oral delivery
EP1490031A1 (en) * 2002-03-07 2004-12-29 Vectura Limited Fast melt multiparticulate formulations for oral delivery
US20040003341A1 (en) 2002-06-20 2004-01-01 Koninklijke Philips Electronics N.V. Method and apparatus for processing electronic forms for use with resource constrained devices
AU2003269284A1 (en) * 2002-10-11 2004-05-04 Pharmakodex Limited Pharmaceutical excipients comprising inorganic particles in association with an organic polymeric material and forming a solid reticulated matrix, compositions, manufacturing and use thereof
US20060147389A1 (en) * 2004-04-14 2006-07-06 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
US20060178394A1 (en) 2003-04-14 2006-08-10 Staniforth John N Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
EP1617820B1 (en) * 2003-04-14 2018-03-21 Vectura Limited Dry power inhaler devices and dry power formulations for enhancing dosing efficiency
US20040204439A1 (en) 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
US20060292081A1 (en) * 2003-09-15 2006-12-28 Vectura Limited Methods for preparing pharmaceutical compositions
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
GB0321607D0 (en) 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
GB0330255D0 (en) 2003-12-31 2004-02-04 Vectura Ltd Multiparticulate formulations for oral delivery
GB0408308D0 (en) 2004-04-14 2004-05-19 Vectura Ltd Pharmaceutical compositions
GB0409703D0 (en) 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0410399D0 (en) 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0426301D0 (en) 2004-11-30 2004-12-29 Vectura Ltd Pharmaceutical formulations

Also Published As

Publication number Publication date
US9585834B2 (en) 2017-03-07
DE602005019192D1 (de) 2010-03-18
DK2174653T3 (da) 2014-08-11
US20170216203A1 (en) 2017-08-03
CN101106975A (zh) 2008-01-16
HUE027465T2 (en) 2016-09-28
EP2311434A1 (en) 2011-04-20
SI2311434T1 (sl) 2015-11-30
DK2311434T3 (en) 2015-10-05
CA2589514A1 (en) 2006-06-01
JP5579669B2 (ja) 2014-08-27
US9642800B2 (en) 2017-05-09
GB0425758D0 (en) 2004-12-22
US20080127972A1 (en) 2008-06-05
PL2311434T3 (pl) 2015-12-31
EP1814521B1 (en) 2010-01-27
CN104146960A (zh) 2014-11-19
ES2490240T3 (es) 2014-09-03
SI2174653T1 (sl) 2014-10-30
EP2949317A1 (en) 2015-12-02
WO2006056812A1 (en) 2006-06-01
EP2174653A1 (en) 2010-04-14
ES2340599T3 (es) 2010-06-07
PL1814521T3 (pl) 2010-07-30
EP1814521A1 (en) 2007-08-08
PL2174653T3 (pl) 2014-11-28
PT2174653E (pt) 2014-08-25
EP2949317B1 (en) 2017-01-04
CA2589514C (en) 2014-07-22
JP2011201925A (ja) 2011-10-13
EP2174653B1 (en) 2014-05-14
ES2548884T3 (es) 2015-10-21
JP5339401B2 (ja) 2013-11-13
PT1814521E (pt) 2010-04-16
US20110236492A1 (en) 2011-09-29
IN2014CN04336A (enExample) 2015-09-04
US20160000709A1 (en) 2016-01-07
ATE456363T1 (de) 2010-02-15
EP2311434B1 (en) 2015-07-08
JP2008520307A (ja) 2008-06-19

Similar Documents

Publication Publication Date Title
PT2311434E (pt) Formulações para inalador de pó seco compreendendo partículas modificadas na superfície com aditivos antiaderentes
Dhumal et al. Particle engineering using sonocrystallization: salbutamol sulphate for pulmonary delivery
ES2689704T3 (es) Partículas para usar en una composición farmacéutica
CA2589514E (en) Dry powder inhaler formulations comprising surface-modified particles with anti-adherent additives
Kaialy et al. Dry powder inhalers: mechanistic evaluation of lactose formulations containing salbutamol sulphate
RU2666963C2 (ru) Агрегированные частицы
BR112015030914B1 (pt) Formulação de pó seco
PT2490779E (pt) Processo para melhorar a cristalinidade
US20110105449A1 (en) Dry powder formulations comprising ascorbic acid derivates
WO2019067708A1 (en) METHOD FOR DECREASING PARTICLE SIZE
JP2011500731A (ja) 併用療法
KR102452773B1 (ko) 흡입용 의약 조성물
Malamatari Engineering nanoparticle agglomerates as dry powders for pulmonary drug delivery
Huusko The use of NIR and DSC in studying the crystallization behavior of freeze-dried amorphous lactose
Crisp Solvent-mediated polymorphism and characterisation of inhaled pharmaceuticals
Fröhlich Impact of drug particle shape on permeability and cellular uptake in the lung
Dhillon Engineering of combination particles for improved therapeutic efficacy
HK40018932B (en) A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
XIANG A STUDY OF PARTICLE ENGINEERING AND AEROSOLIZATION IN DRY POWDER INHALERS
BR112018009807B1 (pt) Processo para preparar uma formulação de pó seco que compreende um anticolinérgico, um corticosteroide e um beta-adrenérgico
HK1174570A1 (en) Process for providing particles with reduced electrostatic charges
HK1174570B (en) Process for providing particles with reduced electrostatic charges